2-carbazol-1-yl-ethylamine | 854822-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-carbazol-1-yl-ethylamine
• 英文别名: 2-Carbazol-1-yl-aethylamin；9H-Carbazole-1-ethanamine；2-(9H-carbazol-1-yl)ethanamine
• CAS: 854822-53-0
• 化学式: C₁₄H₁₄N₂
• 分子量: 210.279
• InChiKey: HWTAKVLMACWHLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  9H-咔唑-1-甲酸 在 1,4-二氧六环 、 氯化亚砜 、 ammonium polysulfide 、 氯仿 、 氨 、 镍 、 甲苯 、 三氯氧磷 作用下， 生成 2-carbazol-1-yl-ethylamine
  参考文献：
  名称：

  Manske; Kulka, Canadian Journal of Research, Section B: Chemical Sciences, 1950, vol. 28, p. 443,451

  摘要：

  DOI：

文献信息

• [EN] AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT SPÉCIFIQUES D'AXL POUR LE TRAITEMENT DU CANCER
  申请人：GENMAB AS

  公开号：WO2017009258A1

  公开（公告）日：2017-01-19

  The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.

  本公开涉及抗体药物偶联物（ADCs）与人类AXL结合，特别用于治疗耐药或难治性癌症。
• PEPTIDE FOR INDUCING MAST CELL-SPECIFIC APOPTOSIS AND USE THEREOF
  申请人：CAREGEN CO., LTD.

  公开号：US20160075739A1

  公开（公告）日：2016-03-17

  A peptide according to the present invention can perform a function identical or similar to the function of natural CTLA-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (CD80 and CD86) to inhibit activity of T cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, IL-2 and IFN-γ). As a result, a composition comprising the peptide according to the present invention exhibits excellent effects in terms of preventing, treating, or improving Th1-mediated immune diseases. Therefore, the superior activity and stability of the peptide according to the present invention can be useful when applied to medicine, quasi-drugs, and cosmetics.

  根据本发明的肽能够执行与天然CTLA-4相同或类似的功能，并且由于体积小，具有出色的皮肤渗透性。根据本发明的肽有效地结合到抗原呈递细胞表面蛋白（CD80和CD86）上，以抑制T细胞的活性，从而能够抑制炎症细胞因子（例如IL-2和IFN-γ）的表达。因此，包含根据本发明的肽的组合物在预防、治疗或改善Th1介导的免疫性疾病方面表现出优异效果。因此，根据本发明的肽的优越活性和稳定性在应用于药物、准药物和化妆品时可能非常有用。
• [EN] ANTIBODIES BINDING AXL<br/>[FR] ANTICORPS SE LIANT À AXL
  申请人：GENMAB AS

  公开号：WO2016005593A1

  公开（公告）日：2016-01-14

  The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

  本公开涉及抗AXL抗体、免疫结合物、组合物以及使用这些抗AXL抗体、免疫结合物或组合物治疗癌症的方法。
• Water-Soluble CC-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20090318668A1

  公开（公告）日：2009-12-24

  This invention relates to novel analogs of the DNA-binding alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

  这项发明涉及DNA结合烷基化剂CC-1065的新型类似物及其结合物。此外，该发明涉及用于制备上述剂和它们的结合物的中间体。这些结合物设计为在一个或多个激活步骤之后以及/或由结合物控制的速率和时间跨度下释放它们的（多种）荷载，以便选择性地传递和/或可控地释放一个或多个所述的DNA烷基化剂。这些剂、结合物和中间体可用于治疗以不良（细胞）增殖为特征的疾病。例如，这项发明的剂和结合物可用于治疗肿瘤。
• PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING ANGIOGENIC DISEASES COMPRISING INHIBITORS OF NUP153 GENE EXPRESSION OR NUP153 ACTIVITY AS ACTIVE INGREDIENT
  申请人：INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

  公开号：US20150023973A1

  公开（公告）日：2015-01-22

  The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.

  本发明提供了一种用于预防或治疗血管生成性疾病的药物组合物，包括作为活性成分的NUP153基因表达或NUP153活性的抑制剂，并提供了一种筛选用于预防或治疗血管生成性疾病的药剂的方法。根据本发明，抑制NUP153基因表达或NUP153活性会减少促血管生成因子（VEGF、HGF和bFGF）的mRNA从细胞核的输出。此外，抑制NUP153基因表达或NUP153活性的作用会通过抑制侵袭和管道形成以剂量依赖的方式抑制血管生成，而不显示毒性。因此，本发明的药物组合物可用于预防或治疗各种与血管生成相关的疾病，而本发明的筛选方法可有价值地用于发现新的用于预防或治疗血管生成性疾病的药剂。